Study #2017-0495
A Phase 2 Single-Arm, Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax in Combination with Ruxolitinib in Subjects with Myelofibrosis
Study Status
Open
Treatment Agent
Navitoclax, Ruxolitinib
Principal Investigator
Naveen Pemmaraju
Description
The goal of this clinical research study is to learn if the combination of navitoclax and ruxolitinib can help to control myelofibrosis. The safety of this drug combination will also be studied.
General Information
Disease Group: Malignant neoplasms stated as primary lymphoid haematopoietic
Treatment Agent: Navitoclax, Ruxolitinib
Treatment Location: Both at MD Anderson & Other Sites
Sponsor: Abbvie
Study Status
IRB Review and Approval Date: 06/13/2018
Recruitment Status: Open
Projected Accrual: 10 -15 sites, total of 34 patients is overall goal
Resources and Links
Information and next steps
Disease:
Malignant neoplasms stated as primary lymphoid haematopoietic
Study phase:
Phase II
Physician name:
Naveen Pemmaraju
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789